PDS Biotechnology Corporation reported a net loss of $9.0 million, or $0.19 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $10.7 million, or $0.29 per basic and diluted share, for the same period in 2024. Research and development expenses were $4.6 million, down from $6.8 million in the prior year period, primarily due to lower manufacturing, clinical expenses, and personnel costs. General and administrative expenses were $3.6 million, up from $3.4 million, mainly due to higher professional fees. Total operating expenses decreased to $8.1 million from $10.2 million. Net interest expense increased to $0.9 million from $0.5 million, largely due to lower interest income. During the quarter, the company completed the VERSATILE-002 Phase 2 trial of PDS0101 with pembrolizumab in HPV16-positive recurrent/metastatic head and neck cancer and announced plans to seek an expedited approval pathway for the ongoing VERSATILE-003 Phase 3 trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041805), on November 13, 2025, and is solely responsible for the information contained therein.
Comments